Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.3K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le, Jennifer N. Durham, Kellie N. Smith et al. · Science · 2017 · 6.6K citations

Life Sciences, Immunology, Oncology +17